Company: OTSA
Filing Date: 2025-07-16
Form Type: F-1/A
Source: 0001213900-25-064434
Chunk: 168

Company: OTSAW Ltd
Filing Date: 2025-07-16
Form: F-1/A
Chunk 168
---
 customers in the region. Over the next 1 to 3 years, we plan to expand our operations in Europe by increasing the size of our team to 20 employees. In parallel, we are preparing to meet applicable regulatory and certification requirements in the United States and Europe. These include obtaining UL and FCC certifications for the United States market, and CE certification for the European market. We expect to complete these compliance processes as part of our international expansion strategy. In particular, we have applied for CE certification for TransCar 5.0 and our application is currently under design review. We expect to complete the CE certification process and acquire CE certification for TransCar 5.0 by the second quarter of 2026. We intend to obtain UL and FCC certifications in the United States for TransCar 5.0 after CE certification has been obtained. We have not initiated the regulatory certification process for any of our other product lines at this time. There can be no assurance that we will receive CE, UL or FCC certification for TransCar 5.0 or our other products as and when we commence the certification process, or that we will receive such certifications within our expected timeline, if at all. Failure to obtain these certifications may impact our ability to market and sell TransCar 5.0 or our other products in the United States and Europe and could materially affect our business, financial condition and results of operations. 101 In relation to the healthcare facilities management industry, our joint venture with Swisslog Healthcare provides us with an immediate customer base and market access to hospitals and healthcare facilities in Europe and Southeast Asia, which are regions with a particularly high barrier to entry. Swisslog Healthcare’s strong reputation in the healthcare industry, along with the value of its TransCar hospital intralogistics product, are effectively complemented by our existing scalable AMR security patrol and last -miledelivery AMR platforms, UV -Cdisinfection systems and our core software technologies. Additionally, we will further penetrate the healthcare intralogistics markets in Europe and Southeast Asia by upgrading and “future -proofing” the existing TransCar AGV systems with our core software technologies. We are confident in our ability to take advantage of current market opportunities because hospitals worldwide are expected to upgrade their intralogistics systems to solve labor shortage and productivity challenges that were particularly exposed during the COVID -19pandemic. We envision to replace the conventional labor -intensivehigh and low volume intralogistics, disinfection, and security patrol functions in hospital and healthcare facilities with our AI -enabled